<DOC>
	<DOCNO>NCT00577122</DOCNO>
	<brief_summary>The purpose study evaluate impact MPA alone combination low dose oral chemotherapy patient ER- PR- advance breast cancer .</brief_summary>
	<brief_title>Medroxyprogesterone +/- Cyclophosphamide &amp; Methotrexate Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine clinical benefit rate ( complete response [ CR ] + partial response [ PR ] + stable disease [ SD ] &gt; = 6 month ) medroxyprogesterone acetate ( MPA ) monotherapy MPA + low dose oral cyclophosphamide methotrexate ( ldoCM ) patient refractory hormone receptor negative metastatic breast cancer . SECONDARY OBJECTIVES : I . To evaluate toxicity MPA MPA + ldoCM patient population . II . To explore relationship MPA trough level clinical benefit . III . To explore genetic determinant MPA bioavailability trough concentration . IV . To explore potential surrogate biologic activity include Nm-23 expression primary tumor , change Nm-23 expression skin , change plasma thrombospondin ( TSP ) -1 , change plasma plasminogen activator inhibitor ( PAI ) -1 antigen activity . OUTLINE : Patients assign 1 2 treatment arm . COHORT I : Patients receive MPA orally ( PO ) daily ( QD ) . COHORT II : Patients receive MPA Cohort I , cyclophosphamide PO QD , methotrexate PO twice daily ( BID ) day 1 2 every week . In arm , treatment continue absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast measurable locally recurrent metastatic disease Primary tumor must ER negative PR negative Patients must postmenopausal Patients may 3 prior chemotherapy regimens recurrent/metastatic disease Adequate organ function evidence laboratory study outline section 3.6 protocol Patients treat , asymptomatic brain metastasis eligible provide chronic steroid therapy require Patients must extensive pleural effusion ascites Patients must history DVT pulmonary embolism w/in past 12 mo Patients must chemotherapy hormonal therapy within 2 week study entry Patients must radiation therapy within 1 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Medroxyprogesterone progesterone acetate ( MPA )</keyword>
	<keyword>Cyclophosphamide plus Methotrexate</keyword>
</DOC>